New Retina Radio:

New Retina Radio Meeting Coverage

New Retina Radio Meeting Coverage

12.03.21

PALADIN for DME and ROP Updates From the ICROP

Extending treatment duration in patients with DME whose disease is responsive to steroid therapy could be instrumental in ensuring that visual disruption is kept at a minimum. How might the 3-year results from the PALADIN study guide treatment in the near future? Michael Singer, MD, reviewed data from a phase 4, 3-year, real-world study of patients whose DME was managed with fluocinolone acetonide 0.19 mg implant (Iluvien, Alimera Sciences). And NRR sat down with R.V. Paul Chan, MD, MSc, MBA, who summarized updates to ROP therapy as outlined in the 3rd edition of the International Classification of Retinopathy of Prematurity. What are the updates, and what spurred the ICROP to make them? Tune in to find out. This editorially independent podcast is supported with advertising.

Other Podcast Episodes

08.21.25

ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human Graders

John Kitchens, MD; Krishna Mukkamala, MD

06.12.25

Duke AVS Clips: PVR, DR, Imaging, and MTM

Jason Hsu, MD; Majda Hadziahmetovic, MD; Aleksandra Rachitskaya, MD; Gavin Tan, MD, PhD, FRCSed

06.09.25

Duke AVS Clips: Pediatrics, Anesthesia Trends, and AI

Lejla Vajzovic, MD; Jason Fan, MD; Glen J. Jaffe, MD

06.05.25

Duke AVS Clips: Gene Therapy, RDs, IOLs, and PVDs

Avni P. Finn, MD, MBA; Lejla Vajzovic, MD, MBA; David Zacks, MD, PhD; Dilraj S. Grewal, MD; Xi Chen, MD, PhD; Yuxi Zheng, MD; Durga Borkar, MD; and Yannek I. Leiderman, MD, PhD

05.29.25

ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data

Marion Munk, MD, PhD; and Diana Do, MD

05.22.25

ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline

David Miller, MD; and Robert Wang, MD

11.07.24

AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMD

Jeremiah Brown, MD, MS; and Eric Schneider, MD

Show More